Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.44 |
| ▸ | METAP2 | P50579 | 8/20 | 0.41 |
| ▸ | METAP1 | P53582 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5709564 | 1.00 | REN (0.44) | RENMETAP2METAP1 | |
| SCHEMBL7272557 | 0.88 | REN (0.49) | RENMETAP2METAP1 | |
| SCHEMBL8910518 | 0.88 | REN (0.49) | RENMETAP2METAP1 | |
| SCHEMBL7277378 | 0.87 | REN (0.47) | RENMETAP2METAP1 | |
| SCHEMBL9507429 | 0.86 | REN (0.45) | RENMETAP2METAP1 | |
| SCHEMBL9506691 | 0.86 | REN (0.45) | RENMETAP2METAP1 | |
| SCHEMBL9503799 | 0.86 | REN (0.45) | RENMETAP2METAP1 | |
| SCHEMBL8203573 | 0.85 | REN (0.46) | RENMETAP2METAP1 | |
| SCHEMBL7278692 | 0.85 | REN (0.46) | RENMETAP2METAP1 | |
| SCHEMBL10520380 | 0.84 | REN (0.43) | RENMETAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | claimed |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | claimed |
| US-5420127-A | Morpholino-terminated non-peptidyl α-succinamidoacyl aminodiols as anti-hypertensive agents | G. D. SEARLE & CO. (US) | 1995-05-30 | — | — | US | claimed |
| US-4931429-A | RENIN INHIBITORS | G. D. SEARLE & CO. (US) | 1990-06-05 | — | — | US | claimed |
| EP-0313847-A2 | Non-peptidyl alpha-succinamidoacyl aminodiols as anti-hypertensive agents | G.D. Searle & Co. (US) | 1989-05-03 | — | — | EP | claimed |
| EP-0310071-A2 | Non-peptidyl alpha-aminoacyl aminodiol carbamates as anti-hypertensive agents | G.D. Searle & Co. (US) | 1989-04-05 | — | — | EP | claimed |
| EP-0310070-A2 | Alpha-aminoacyl beta-aminoacyl aminodiols as anti-hypertensive agents | G.D. Searle & Co. (US) | 1989-04-05 | — | — | EP | claimed |
| EP-0310073-A2 | Non-peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents | G.D. Searle & Co. (US) | 1989-04-05 | — | — | EP | claimed |
| JP-1113364-A | — | — | None | — | — | JP | disclosed |
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | disclosed |
| EP-0609689-B1 | Process for preparing optically active 2-aminopropanal | NIPPON KAYAKU KK (JP) | 1997-06-04 | — | — | EP | disclosed |
| US-5428064-A | Renin inhibitor | G.D. SEARLE & CO. (US) | 1995-06-27 | — | — | US | disclosed |
| US-5428054-A | Renin inhibitor | G. D. SEARLE & CO. (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0310071-A2 | Non-peptidyl alpha-aminoacyl aminodiol carbamates as anti-hypertensive agents | G.D. Searle & Co. (US) | 1989-04-05 | — | — | EP | disclosed |
| EP-0310070-A2 | Alpha-aminoacyl beta-aminoacyl aminodiols as anti-hypertensive agents | G.D. Searle & Co. (US) | 1989-04-05 | — | — | EP | disclosed |
| EP-0295294-A1 | PEPTIDYLAMINODIOLS | ABBOTT LABORATORIES (US) | 1988-12-21 | — | — | EP | disclosed |
| WO-1988005050-A1 | PEPTIDYLAMINODIOLS | ABBOTT LABORATORIES (US) | 1988-07-14 | — | — | WO | disclosed |
| EP-0229667-A2 | Peptidylaminodiols | ABBOTT LABORATORIES (US) | 1987-07-22 | — | — | EP | disclosed |
| EP-0189203-A2 | Peptidylaminodiols | ABBOTT LABORATORIES (US) | 1986-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | BACE1, BACE2, APP | REN 2199/4885METAP2 55/4885METAP1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.